25th meeting of the Technical Advisory Group on Immunization and Vaccine Preventable Diseases in the Western Pacific Region

22 August 2016

On 26-29 July 2016 the Western Pacific Region held the 25th Meeting of the Technical Advisory Group on Immunization and Vaccine-Preventable Diseases. 

Participants discussed progress towards achieving the targets and indicators for the polio endgame; elimination of measles, rubella, and maternal and neonatal tetanus; and accelerated control of hepatitis B and Japanese encephalitis (JE). Discussions also covered evidence- based introduction of new vaccines and the decision making processes, as well as vaccine safety and regulatory capacity. 

A side session was held with representatives from national immunization technical advisory groups (NITAGs) to discuss successes and challenges in evidence-based immunization decision making. 

tagWPR.jpg

TAG's key recommendations included setting a regional rubella elimination target date of 2020; as well as finalizing the Regional Strategies and Plan of Action on measles and rubella.   Member States were recommended to prioritize available stocks of IPV for high risk areas and to explore the programmatic feasibility of using a fractional dose via intra-dermal administration. The TAG recommended the use of a JE incidence target of < 0.5 cases per 100,000 population in the targeted population (typically children aged <15 years) in affected areas.   The TAG re-emphasized the importance of strengthening immunization decision making through strong NITAGs or equivalents. Particular attention was given to the need to support the Pacific Island Countries as well as developing regional NITAG networks. The TAG reiterated the importance of establishing a second year of life platform for immunization as an opportunity to reach all children. Member States were encouraged to work with WHO and partners to ensure vaccine security and avoid stock outs through regular vaccine forecasting, timely procurement and adequate resource allocation, making use of the Middle Income Country strategies and the Vaccine Product, Price and Procurement (VP3) platform to overcome potential risks to vaccine security. Member States and the Region were encouraged to take a cautious approach when considering the use of dengue vaccine, closely following advice in the current position paper and any additional recommendations from SAGE.


The meeting report with complete conclusions and recommendations will be available shortly online.

 

Related News & Events

  • 13 -24
    May
    France

    Advanced Course of Vaccinology

    ADVAC 20th
    Fondation Mérieux & Université de Genève
    Les pensieres, Veryier-du-lac
  • Network

    Are you the next GNN chair?

    26.03.2019

    The secretariat of the Global NITAG Network is proud to announce an open call for nomination for the new chair for a 2 year mandate.  The vacant will be generated when Pr Anthony Harnden ends his term in June 2019.

    Read more
  • Belgium
    SAGE

    New advisory report for the vaccination against Tick-Borne Encephalitis

    21.03.2019

    The Superior Health Council (SHC) received 2 requests for an advisory report by letter, on May 12 2017 from the Risk Management Group (FPS Health, Food Chain Safety and Environment) and on November 14 2018 from the federal Minister of Health. Both requests are treated in this advisory report.
     

    Read more